臺灣博碩士論文加值系統

在醫藥產業裡時常可以見到原廠藥專利期過後，學名藥進入市場產生價格競爭的狀況，在價格競爭的影響之下，原廠藥品營業額劇烈下滑，這樣的情況稱為”專利懸崖“，因此原廠藥商必須提早採取對應的策略以因應這樣的情況發生，避免專利到期後公司的營運受到影響。

個案公司為美國知名藥廠，個案藥品在2014年貢獻個案公司14億美元的營業額，是B肝藥品裡的領導品牌，這個個案研究主要探討的問題是個案公司在面臨專利到期後如何採取的行銷策略，與個案藥品在專利到期後為何仍然可以維持市場領先地位，以及台灣的全民健保如何影響個案公司行銷策略佈局。

本個案研究藉由SLEPT外部環境分析、五力分析與行銷組合分析等各個關鍵因素來歸納出專利期過後行銷策略的成功因素，期能提供品牌藥商面臨專利期過後在台灣面對市場競爭時兼具行銷學理與實務可行的策略架構。

In the pharmaceutical industry, it is not unusual to see the drugs go off-patent and become generic drugs. When the top selling drugs go off-patent within a short period of time, a serious issue called “patent cliff” arises opening opportunities for generic drug manufacturers. The major problem for branded drugs going off-patent is the fierce competition with generic drugs that may lead to the “price war” and rapid sales erosion, this is so called the “patent cliff”. The brand-name drug companies are at risk of losing billions in sales due to the patent cliff in the recent years as several blockbuster drugs will lose patent. Upon patent expiry, lower priced generic drugs may reduce the revenue for the brand-name drugs by as much as 90%. Therefore, pharmaceutical companies should start to plan for patent expiry as early as possible to cope with the coming of patent expiry of products.

Case drug, one of the most blockbuster products in the case company, is going off-patent in 2015 in US. In the recent years, the case product has contributed more than 1.4 billion sales for the case company; furthermore, it has maintained the market leader position among all the hepatitis B drugs in the market.

The strategic marketing is to identify of one or more sustainable competitive advantages a firm has in the markets it serves, and allocation of resources to exploit them. In order to study how a pharmaceutical company manages its strategies to face the issue of patent expiry, this case study firstly use strategic marketing analysis of the macro-environment and micro-environment factors that influence the strategic decision of the case company, then compare the strengthens and weaknesses of the case drug among all the hepatitis B drugs to better understand the competitive advantages of the case product. After the analysis of the external and internal situation of the case company, the strategic marketing of the case company has been examined to see how does the case company adjust its marketing strategies in the environment of National Health Insurance in Taiwan. Finally, the conclusion and suggestion of the marketing strategies that can be applied to deal with the patent expiry in Taiwan will be provided for the pharmaceutical companies in the similar scenario. These strategies include leverage the brand equity, enhance the customer loyalty, accelerate innovation development and defend the patent. The goal of this study is to create a theoretical and practical framework for the strategy planning for the pharmaceutical companies.

Abstract i
List of Figures vi
List of Tables viii
Chapter 1 Introduction 1
1.1 Background of Research 1
1.2 Purpose of the Study 1
1.3 Structure of the Thesis 1
Chapter 2 Methodology 3
Chapter 3 Literature Review 5
3.1 Strategic Market Management 5
3.1.1 Five Forces Analysis 6
3.1.2 SWOT 9
3.1.3 Pharmaceutical Market Pricing Strategies 10
3.1.4 Brand Equity of The Brand-Name Drugs 12
3.1.5 The New Drug Development Process 14
3.1.6 Product Life Cycle Management 16
3.2 The Market Competition After Patent Expiry of Brand-name Drugs 22
3.2.1 Loss of Exclusivity (LOE) of Pharmaceutical Market- The Patent Cliff 25
3.3 Strategies Used to Defend Pharmaceutical Brands from Generics 28
3.3.1 Defense Strategies with Marketing Mix Components 29
3.3.2 Pre-expiration Strategies in The Pharmaceutical Industry 30
3.4 The National Health Insurance (NHI) Program 32
3.4.1 Taiwan NHI Overview 33
3.4.2 The Global Budget Payment System and Reimbursement System 33
3.4.3 The Pay-For-Performance System 34
3.4.4 NHI Drug Expenditure Target Allocation System (DET) 34
3.4.5 Drug Life Cycle Under Taiwan NHI 42
3.4.6 The Medical Procurement Process 45
Chapter 4 Introduction of the Case Company and Product 47
4.1 Introduction of the Case Company 47
4.2 Introduction of the Case Product 48
4.2.1 Key Facts of Case Product 49
4.2.2 Sales and Price of Case Product 50
Chapter 5 Hepatitis B Drug Market Analysis 52
5.1 The Situation of HBV disease 52
5.2 Key Facts of HBV 54
5.3 Geographical distribution 55
5.4 Treatment for Hepatitis B 56
5.5 Hepatitis B Drugs 58
Chapter 6 Strategic Marketing Analysis of Hepatitis B Drug in Taiwan 60
6.1 SLEPT Analysis of Hepatitis B in Taiwan 60
6.1.1 Social 60
6.1.2 Legal 61
6.1.3 Economic 64
6.1.4 Political 65
6.1.5 Technology 65
6.2 Five Forces Analysis of the Case 66
6.2.1 Rivalry Among Existing Competitors 66
6.2.2 Threat of New Entrants 68
6.2.3 Bargaining Power of Suppliers 69
6.2.4 Threat of Substitute Products 69
6.2.5 Bargaining Power of Buyers 69
6.3 SWOT Analysis of the Case Product 71
6.4 Marketing Mix of the Case 72
6.4.1 Product 72
6.4.2 Price 73
6.4.3 Place 75
6.4.4 Promotion 77
Chapter 7 Conclusion and Suggestion- The LEAD Strategy 81
7.1 Leverage on the Brand Equity 82
7.2 Enhance the Customer Royalty 83
7.3 Accelerate Innovation 86
7.4 Defend the Patent 86
7.5 Research Finding 89
7.6 Contribution of the Research 89
7.7 Limitations and Directions for Future Research 91
Reference 92
Appendix 1 98
Appendix 2 101

1.Porter, M. E. (2002). How competitive forces shape strategy. D. Faulkner, Strategy. Critical Perspectives on Business and Management, 3-17.
2.Porter, M. E. (2008). Competitive advantage: Creating and sustaining superior performance. Simon and Schuster.
3. Dul, J., & Hak, T. (2008). Case study methodology in business research. Routledge.
4.Aaker, D. A., & McLoughlin, D. (2009). Strategic market management: global perspectives. John Wiley & Sons
5.Lu, Z. J., & Comanor, W. S. (1998). Strategic pricing of new pharmaceuticals. Review of Economics and Statistics, 80(1), 108-118.
6.Dean, J. (1969). Pricing pioneering products. The Journal of Industrial Economics, 165-179.
7.Prajapati, V., Tripathy, S., & Dureja, H. (2013). Product lifecycle management through patents and regulatory strategies. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 13(3), 171-180.
8.Frank, R. G., & Salkever, D. S. (1991). Pricing, patent loss and the market for pharmaceuticals (No. w3803). National Bureau of Economic Research.
9.Frank, R. G., & Salkever, D. S. (1997). Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy, 6(1), 75-90.
10.Frank, R. G. (2001). Prescription drug prices: why do some pay more than others do? Health Affairs, 20(2), 115-128.
11.Grabowski, H. G., & Vernon, J. M. (1992). Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics, 331-350.
12.Grabowski, H., Long, G., & Mortimer, R. (2013). Recent trends in brand-name and generic drug competition. Journal of medical economics, 17(3), 207-214.
13.Hurwitz, M. A., & Caves, R. E. (1988). Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. Journal of Law and Economics, 299-320.
14.Kanavos, P., Costa-Font, J., & Seeley, E. (2008). Competition in off-patent drug markets: Issues, regulation and evidence. Economic policy, 23(55), 500-544.
15.Wilkie, D. C., Johnson, L. W., & White, L. (2012). Strategies used to defend pharmaceutical brands from generics. European Journal of Marketing, 46(9), 1195-1214.
16.Berndt, E. R., Kyle, M., & Ling, D. (2003). The long shadow of patent expiration. Generic entry and Rx-to-OTC switches. In Scanner data and price indexes (pp. 229-274). University of Chicago Press.
17.Regan, T. L. (2008). Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization,26(4), 930-948.
18.Wiggins, S. N., & Maness, R. (2004). Price Competition in Pharmaceuticals: The Case of Anti‐infectives. Economic Inquiry, 42(2), 247-263.
19.Pearce, J. A. (2006). How companies can preserve market dominance after patents expire. Long Range Planning, 39(1), 71-87.
20.Scott Morton, F.M. (2000), “Barriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry”, International Journal of Industrial Organization, Vol. 18 No. 7, pp. 1085-104.
21.Reiffen, D., & Ward, M. R. (2007). ‘Branded Generics’ as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics, 28(4‐5), 251-265.
22.Hou, J., Liu, Z., & Gu, F. (2005). Epidemiology and Prevention of Hepatitis B Virus Infection. International Journal of Medical Sciences, 2(1), 50–57.
23.Caves, R. E., Whinston, M. D., Hurwitz, M. A., Pakes, A., & Temin, P. (1991). Patent expiry, entry, and competition in the US pharmaceutical industry. Brookings papers on economic activity. Microeconomics, 1-66.
24.Kvesic, D. Z. (2008). Product lifecycle management: marketing strategies for the pharmaceutical industry. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 8(4), 293-301.
25.Gatignon, H., Robertson, T. S., & Fein, A. J. (1997). . International Journal of Research in Marketing, 14(2), 163-176.
26.Hollis, A. (2002). The importance of being first: evidence from Canadian generic pharmaceuticals. Health Economics, 11(8), 723-734.
27.簡榮南, (2012), 慢性 B 型肝炎治療的現況. 內科學誌, 23(6), 377-382.
28.譚令蒂, 洪乙禎, & 謝